Cutaneous malignant melanoma (CMM) is the most serious cutaneous malignancy. CMM patients often develop an immune response to their tumours. Conflicting evidence suggests that IL-10 may contribute to tumour escape from the immune response, but may also have an anti-tumour effect. To distinguish between these models and to determine whether genotypes associated with differential IL-10 expression confer susceptibility to and/or influence prognosis in CMM, 165 CMM patients and 158 controls were genotyped for IL-10 promoter SNPs by ARMS-PCR. The IL-10 −1082 AA low expression genotype was increased in incidence among CMM patients (P = 0.04). In addition, IL-10 genotypes showed significant associations with three of four prognostic indicators examined; IL-10 −1082 GG (P = 0.02) and −1082, −819 and −592 compound high expression (P = 0.03) genotypes were associated with horizontal (non-invasive) tumour growth; IL-10 −1082 AA low expression genotype was associated with more advanced (Stage II-IV) disease (P = 0.04); finally, the IL-10 −1082 AA (P = 0.005) and compound low expression (P = 0.009) genotypes were significantly increased in frequency among patients with thicker primary Vertical growth phase tumours. These results indicate that genotypes associated with high levels of IL-10 expression in vitro are protective in CMM, while low expression genotypes are a risk factor for more advanced/poorer prognosis disease and may confer susceptibility to CMM. Although the influence of IL-10 on melanoma development is likely to be complex, these results support recent findings that IL-10 has an anti-tumour effect in CMM, possibly via inhibition of angiogenesis. Genes and Immunity (2001) 2, 25-31.
Introduction
Cutaneous malignant melanoma (CMM) is the most serious cutaneous malignancy and is increasing in frequency among most Caucasian populations, where the most important risk factor is exposure to ultraviolet (UV) light. 1 Relatively little is known of the genetic factors that mediate susceptibility to and prognosis in sporadic CMM, although polymorphisms associated with the melanocortin-1 receptor (MCR1) may be associated with susceptibility to CMM 2 and polymorphisms associated with the vitamin D receptor and the cytochrome P450 CYP2D6 genes have been implicated in modulating prognosis in this tumour. 3, 4 In addition, several lines of evidence suggest that CMM patients develop an immune response to their tumours, 5 although in individuals with CMM, this anti-tumour immune response is insufficient to abrogate tumour development. This is supported by studies from various laboratories, including our own, which variably, but not unanimously, implicate human leukocyte antigen (HLA) DQB1 polymorphisms in CMM susceptibility and prognosis.
cytokine and elevated IL-10 expression has been implicated in inhibition of the anti-tumour T cell immune response in CMM, leading to tumour escape. In support of this, elevated serum IL-10 levels have been reported in many cancers, including CMM. 9 Increased serum levels may also correlate with stage of disease. 10 IL-10, produced by melanoma cells, can also act as an autocrine growth factor. 11 Conversely, other studies have described IL-10 associated anti-tumour activities in CMM. In particular, transfection of the murine IL-10 gene into human melanoma cells that did not express IL-10, resulted in a loss of metastasis and significant inhibition of tumour growth, via inhibition of angiogenesis. 12 Based on the above, and to distinguish whether high constitutive levels of IL-10 have a tumour promoting or anti-tumour influence in CMM, genotyping for IL-10 −1082, −819 and −592 single nucleotide promoter polymorphisms (SNPs) in a series of 165 CMM patients was performed, utilizing DNA extracted from diagnostic histopathological formalin-fixed, wax-embedded tissues. These polymorphisms have been reported to define 'high', 'medium' and 'low' expression genotypes for IL-10. 13, 14 The following clinical and pathological markers were examined as indicators of prognosis: initial growth phase (horizontal vs vertical), mitotic count within vertical growth phase tumours, Breslow depth of invasive CMM and stage of disease. 15 Among these factors, Breslow thickness at presentation is the most important single prognostic indicator in CMM, 16 with 5-year survival values ranging from 93% for tumours Ͻ1.5 mm thick, P values and odds ratios are given where P р 0.05. P values for non-significant trends (P = 0.05-0.10) are also given. All other P values (-in table) were non-significant. compared with 67% for 1.5-3.49 mm tumours, to 37% for tumours Ͼ3.5 mm thick. 17 In addition, IL-10 genotypes were compared between this CMM series and a series of 158 unrelated controls, to determine whether IL-10 genotype influences susceptibility to CMM.
Results
All control samples were successfully genotyped for all three IL-10 promoter SNPs. Of the 165 CMM cases, 153 were genotyped for IL-10 −1082, 150 for −819 and all cases for −592, according to DNA availability. High, medium and low expression genotypes were assigned from these results, according to the definitions of Perrey et al, 14 ie, −1082, −819, −592 GCC/GCC was defined as 'high', GCC/ACC and GCC/ATA as 'medium' and ACC/ACC, ACC/ATA and ATA/ATA as 'low' expression genotypes. Considering IL-10 −1082 SNP genotypes alone, GG was considered as a 'high' expression genotype, GA as 'medium' and AA as a 'low' expression genotype. 13, 14 Results for all three promoter SNPs and for the combined expression genotypes were compared between CMM cases and the series of 158 controls. From Table 1 it can be seen that the IL-10 −1082 AA low expression genotype was significantly increased among CMM patients compared with controls (26.8% vs 17.1%; P = 0.04; OR = 1.78 (1.03-3.07)), while the −1082 GA medium expression genotype was decreased among Table 2 it can be seen that the IL-10 −1082 GG genotype, associated with high IL-10 expression, was significantly increased in frequency among horizontal (including horizontal in situ) as opposed to vertical growth (invasive) phase primary tumours (38.3% vs 20.4%; P = 0.02; OR = 2.42 (1.14-5.18)).
In agreement with this, the compound IL-10 high expression genotype was similarly significantly increased in frequency among horizontal growth phase primary tumours (37.8% vs 20.8%; P = 0.03; OR = 2.31 (1.06-5.03)). IL-10 genotypes in comparison with stage of disease are shown in Table 3 . Results indicate that the IL-10 −1082 AA genotype, associated with low IL-10 expression, was significantly increased in incidence among patients with Stage II-IV disease, compared to those with Stage I disease (34.5% vs 19.0%; P = 0.04; OR = 2.24 (1.04-4.82)). IL-10 genotypes were also compared with the frequency of mitotic figures in vertical growth phase tumours. Results are shown in Table 4 , from which it can be seen that no IL-10 genotypes were significantly associated with more rapidly dividing tumours. However, there was a nonsignificant trend towards an increased frequency of the IL-10 −1082 AA low expression genotype (33.3% vs 23.8%) and compound low expression genotype (33.3% vs 22.0%) among patients with more rapidly dividing vertical growth phase (invasive) tumours. Finally, IL-10 genotypes were compared among patients with vertical growth phase tumours stratified according to the Breslow thickness of their primary tumour (Table 5) . At a cut-off point of 0.74 mm, the IL-10 −1082 AA low expression genotype was increased in frequency among tumours with a thickness Ͼ0.74 mm, at a marginal level of significance (2/20 (10.0%) vs 26/82
Genes and Immunity (31.7%); P = 0.06). The compound IL-10 low expression genotype also showed a nonsignificant increase in frequency among tumours thicker than 0.74 mm (2/20 (10.0%) among thinner tumours vs 23/75 (30.7%) among thicker tumours; P = 0.09). Despite the large differences in frequency between the two tumour thickness groups, the number of tumours of greater than 0.74 mm Breslow thickness and of IL-10 low expression genotype was too small to achieve significance. When stratifying tumours according to Breslow thickness of greater or less than 1.4 mm, the IL-10 −1082 low expression genotype was sig- In all of the above comparisons with known prognostic indicators in CMM, no significant associations were seen with the IL-10 −819 and −592 SNPs considered individually, although a number of nonsignificant trends (P = 0.05-0.10) were observed.
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Discussion
This study was performed to determine whether polymorphisms associated with differential IL-10 production influence susceptibility to and/or prognosis in CMM. In particular, we wished to ascertain whether polymorphisms in the IL-10 promoter, associated with high IL-10 expression in vitro confer a tumour promoting or tumour inhibiting phenotype, so as to distinguish between conflicting models of the influence of IL-10 on melanoma growth. Results obtained in the study indicated a small, but significant association between the IL-10 −1082 AA low expression genotype and susceptibility to CMM. In addition, IL-10 expression genotypes showed significant associations with three out of the four prognostic indicators examined. Firstly, the IL-10 −1082 GG and compound high expression genotypes were significantly increased in frequency among horizontal or non-invasive growth phase tumours, compared with vertical (invasive) growth phase tumours. Secondly, the IL-10 −1082 AA low expression genotype was significantly increased in frequency among patients with more advanced Stages (II-IV) of disease. Thirdly, and most significantly, the IL-10 −1082 AA and compound low expression genotypes were significantly increased in frequency among thicker vertical growth phase tumours. This was the strongest association found in this study, which is of particular significance due to the importance of Breslow thickness as a prognostic indicator in CMM. No significant associations between IL-10 genotype and mitotic index of vertical growth phase tumours were demonstrable, but even in this instance, there was a nonsignificant trend towards an increased incidence of IL-10 AA and compound low expression genotypes among more rapidly dividing tumours.
Taken together, the above results strongly suggest that genotypes associated with high levels of IL-10 expression in vitro are protective in the development of CMM, while low expression genotypes are a risk factor for more advanced/poorer prognosis disease. In addition, genotypes associated with low IL-10 expression may also confer susceptibility to CMM, while high expression genotypes are protective. By inference, genotypes conferring low constitutive expression of IL-10 in vivo are a risk factor in CMM, while genotypes conferring high constitutive IL-10 levels are protective.
Many studies have suggested that elevated levels of IL-10 are tumour-promoting in CMM. In vivo, a considerable number of patients with advanced CMM present with elevated serum IL-10 levels 18 and human melanoma cells produce IL-10 in vivo. 19 Other studies have suggested that IL-10 is an autocrine growth factor for human melanoma cells, 11 while IL-10 may be preferentially expressed in metastatic lesions. 20 These findings implicate IL-10 in tumour escape from the immune response, based on its immunosuppressive properties, via suppression of Th-1 type cytokine production, in particular IL-2. Based on these findings alone, it might have been expected that IL-10 genotypes associated with high levels of expression would be protective in CMM, while low expression geno-29 types would be protective. However, the results obtained in this study are in direct opposition to this and are in agreement with recent findings from studies based on the transfection of the murine IL-10 gene into human melanoma cells not expressing IL-10. Huang and colleagues 12 showed that when such transfected cells were introduced into nude mice, IL-10 gene transfer resulted in loss of metastasis and significant inhibition of tumour growth. In addition, the growth of other human or murine cells was also inhibited when they were admixed with IL-10 transfected cells before injection into nude mice. The same workers have shown that IL-10 exerts this antitumour and anti-metastatic activity by inhibiting angiogenesis in vivo, since malignant tumours cannot grow more than 2-3 mm 3 and cannot metastasise without stimulation for the formation of new blood vessels. The results obtained in this preliminary study fully support the latter theory that high IL-10 levels-in this case conferred by genotype-may inhibit tumour development in CMM. The mechanism for this may be via the ability of IL-10 to downregulate synthesis of vascular endothelial growth factor (VEGF)-one of the most potent angiogenic factors-along with IL-1␤, tumour necrosis factor-␣ (TNF␣), IL-6 and matrix metalloproteinase-9 (MMP-9) in tumour-associated macrophages, which also play crucial roles in tumour angiogenesis. However, other studies have shown that IL-10 inhibits tumour metastasis via a natural killer cell-dependent mechanism. 21, 22 In conclusion, results from this study suggest that genotypes associated with high levels of IL-10 expression 
Materials and methods
Patients
Formalin-fixed and paraffin-embedded tissue blocks from 165 CMM patients (presenting in 1986-1993) were retrieved from the files of the Histopathology Department, Southampton General Hospital. All specimens were re-reviewed by two histopathologists (ACB and JMT) and the original diagnoses of CMM confirmed.
Tumour histopathology data
Histopathological prognostic features of each case were assessed, as defined in the literature and used in previous studies, 6, 14 with initial evaluation of the growth phase and thickness (Breslow depth) of the tumour. Radial growth phase lesions were defined as those limited in extent to the epidermis (melanoma in situ) or showing early invasion of the upper dermis, but with dermal nests of melanocytes no larger than those at the dermoepidermal junction, and containing no mitotic figures. Vertical growth phase lesions showed expansile growth within the dermis, evidenced by nests of neoplastic melanocytes that were larger than those at the dermoepidermal junction or the presence of mitotic figures within dermally located melanocytes.
14 For vertical growth phase CMM, the mitotic count per square millimetre of tumour was assessed as nil, 1-6 or Ͼ6.
Clinical follow-up data
The following variables were recorded for each patient, subject to availability of clinical data: gender, age, site of CMM, length of clinical follow-up, presence of recurrent or metastatic tumour, disease-free survival and overall survival time. The clinicopathological stage of each patient at initial presentation for whom full data were available was calculated using the tumour, nodes, metastases system.
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Controls
Controls consisted of stored DNA samples derived from 158 cadaveric and non-cadaveric solid organ and bone marrow donors. All patients and donors were Caucasian.
DNA extraction
DNA was extracted from formalin fixed, paraffin wax embedded tissue blocks as described previously. 6 Briefly, two to five 20 m sections were cut from each tissue block and dewaxed in xylene (Merck Ltd, Poole, UK) and xylene-ethanol washes. DNA was extracted from the resulting cellular material by proteinase K digestion. were included in each reaction and allele specific and internal control primer sequences and PCR product sizes are given in Table 6 .
IL-10 genotyping by ARMS-PCR
All PCR reactions were performed in 10 l reaction volumes and final reagent concentrations were as follows: 1 × AS reaction buffer (ABgene, Epsom, UK), 200 m each dNTP, 12% (w/v) sucrose, 200 m cresol red, 1 m each specific/common primer, 0.2 m each internal control primer (where appropriate), 0.25 units Thermoprime PLUS DNA polymerase (ABgene) and 25-100 ng DNA. Optimised MgCl 2 concentrations for each SNP are given in Table 6 . PCR reactions were performed using a 9600 Thermal Cycler (PE Biosystems, Foster City, CA, USA) or an MWG Primus 96
Plus Thermal Cycler (MWG Biotech UK Ltd, Milton Keynes, UK) according to the following cycling conditions: one minute at 96°, followed by 10 cycles of 96°for 15 s, T o a for each SNP (Table 1) for 50 s, 72°for 40 s; then 20 cycles of 96°for 10 s, 60°for 50 s, 72°for 40 s. PCR products were loaded directly onto 2% agarose gels (containing 0.5 mg/ml ethidium bromide), electrophoresed and visualised by photography under UV transillumination.
Statistical analysis
The frequencies of each IL-10 SNP and combined IL-10 promoter genotype were calculated and compared between the CMM patient series and the controls, using Chi-square analysis on 2 × 2 tables. Fisher's exact P values were calculated for analyses in which one or more variables within 2 × 2 tables was less than 5. Genotype frequencies were similarly compared within patient subgroups according to tumour growth phase, Breslow depth (invasive CMM), mitotic index (vertical growth phase CMM) and stage of disease at presentation. IL-10 allele and genotype association P values were not corrected, since this study was performed for hypothesis generation. Statistical analyses were performed using SPSS (version 10). Odds Ratios (OR) with 95% confidence intervals (CI) were calculated where a particular genotype showed a significantly increased or decreased incidence within the CMM series (Statistical Solutions Inc).
